ADMA Biologics Q2 FY12/25 Earnings Review

DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis on this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Read our full disclaimer, here.

Running With The Big Dogs Now

by Nathan Brinkman

ADMA Biologics is a vertically integrated biopharmaceutical company focused on specialized immunoglobulin (IG) therapies for patients with immune deficiencies and infectious disease risks. Unlike most biopharma,  ADMA operates a highly tangible, infrastructure-heavy business model built on plasma collection, fractionation, and distribution of niche but clinically essential plasma-derived therapeutics.

Since 2021, ADMA has undergone a transformation from a cash-burning development-stage company to a rapidly scaling commercial IgG (antibody) producer. With regulatory approvals secured, plasma center expansion underway, and multi-year manufacturing efficiency gains driving margin expansion, ADMA has positioned itself as an under-the-radar growth story in the human plasma pharmaceutical industry.

After years of investor skepticism, ADMA’s share price has rebounded strongly, driven by record IG demand, operational scaling, and a clear pathway toward sustained profitability. But with IG markets competitive and manufacturing complex, the question remains: Can ADMA maintain its momentum and evolve into a durable mid-cap biologics leader?

Our analysis continues for Inner Circle members. We’ delighted to now offer biotech coverage - now including $MRNA, $BNTX, $IVVD, $ADMA and more to come. Join today before prices rise in January!